TrialStudy of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Trial details
- Registry ID
- NCT04412863
- Phase
- Phase 2
VIR
Vir Biotechnology, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
8Trials in this database
10Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceStudy of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Trial details
- Registry ID
- NCT04856085
- Phase
- Phase 2
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
Trial details
- Registry ID
- NCT04913675
- Phase
- Phase 3
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
Trial details
- Registry ID
- NCT05461170
- Phase
- Phase 2
A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
Trial details
- Registry ID
- NCT05567783
- Phase
- Phase 2
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
Trial details
- Registry ID
- NCT06903338
- Phase
- Phase 3
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
Trial details
- Registry ID
- NCT07128550
- Phase
- Phase 3
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
Trial details
- Registry ID
- NCT07142811
- Phase
- Phase 2
Latest recorded trial changes
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
NCT07128550 · Vir Biotechnology, Inc.
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
NCT05461170 · Vir Biotechnology, Inc.
Primary completion date changed
− Before
Aug 2029
+ After
Nov 2031
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
NCT04856085 · Vir Biotechnology, Inc.
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Mar 2026
+ After
16 Mar 2026
Recruitment status changed
− Before
Active not recruiting
+ After
Completed
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
NCT07142811 · Vir Biotechnology, Inc.
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
NCT06903338 · Vir Biotechnology, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
120 participants (planned)
+ After
124 participants (actual)
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
NCT04856085 · Vir Biotechnology, Inc.
Primary completion date changed
− Before
Jun 2027
+ After
Mar 2026